Photo from wikipedia
Diabetes mellitus in kidney transplant recipients is a risk factor for cardiovascular events and premature death. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) are increasingly used in nontransplant populations to improve diabetes… Click to show full abstract
Diabetes mellitus in kidney transplant recipients is a risk factor for cardiovascular events and premature death. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) are increasingly used in nontransplant populations to improve diabetes control and cardiovascular and renal benefits. Limited literature exists regarding the safety and efficacy of these agents in renal transplant recipients.
Keywords:
mellitus kidney;
glucose cotransporter;
diabetes mellitus;
cotransporter inhibitors;
sodium glucose
Journal Title: Clinical Transplantation
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Transplantation
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!